Abbvie Inc (ABBV)

$202.71 -2.32 (-1.13%)
Market Cap 362.53B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.23
Forward PE 14.41
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 6,681,071
Avg Vol 7,055,928
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 50%
Beta 0.32
Analysts Strong Sell
Price Target $251.03

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
BeefSchnitzerlin
BeefSchnitzerlin May. 8 at 2:25 AM
$ABBV Added this to my divi port today. Been watching a long time waiting for the drop below 200 to buy but missed it. Looks like a potential higher low here today. Solid long term divi compounder, beat and raised and still dropped? Glad it didn't run away without me.
0 · Reply
Garibs
Garibs May. 7 at 7:51 PM
$ABBV why is this getting smoked?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 7 at 4:36 PM
$SLS Keep in Mind - while we Continue to See extended - Near Miraculous ALL POOLED Survival in the REGAL Phase 3 Trial AZA + VEN is the Best Available Treatment (BAT) for Control Arm Patients From the AZA+VEN VIALE-A Phase 3 Trial https://www.venclextahcp.com/aml/side-effects/ven-aza-safety-profile.html - Serious adverse events occurred in 86% of patients with VEN+AZA vs 77% of patients with PBO+AZA - Fatal adverse events occurred in 25% of patients with VEN+AZA vs 22% of patients with PBO+AZA 23% FATALITY RATE for Taking BAT Aza+VEN Subsequently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV including VIALE-M and VIALE-T Trials for AML Remission Maintenance.
0 · Reply
RobinCollins1
RobinCollins1 May. 7 at 4:34 PM
$INMD starting to look like the $ZIM of med-tech. 🧬 Market Cap: $870M / Cash: $530M. Basically no debt, strong FCF, and $82M revenue last quarter. The business is finally stabilizing, but the governance is a wild ride. Moshe Mizrahy's "strategic review" vanished once higher outside bids surfaced. Now, expenses are mounting and operating leverage is suppressed. Is management intentionally keeping the price down while Mizrahy and the company aggressively buy back shares? 🤨 Despite the drama, the aesthetics sector is recovering ($EOLS $ABBV). Even InMode’s growth is returning. With the CFO and Chairman out, the setup is bizarre: A hated, founder-controlled company with half its value in cash, massive buybacks, and a business turnaround that everyone is ignoring. Curious about the full approach? 👉Check the @RobinCollins1
1 · Reply
scottybebs
scottybebs May. 7 at 3:35 PM
$ABBV if your not Ai in this market your nothing this is insane why is it down everyday
0 · Reply
Options_Destroyer
Options_Destroyer May. 7 at 3:23 PM
$ABBV $AMGN $TPR added
0 · Reply
MeanReverter_
MeanReverter_ May. 7 at 3:21 PM
$INMD feels like the $ZIM of med-tech. $870M mkt cap vs ~$530M cash, near zero debt. Still generating ~$82M quarterly revenue with strong margins + FCF — not broken, just mispriced. Story driven by founder control + perception: Mizrahy historical selling, strategic review + rumored bids (incl. foreign interest), then process goes quiet. Buybacks + insider accumulation + exec turnover keep governance discount in play. Aesthetics recovery showing up across $EOLS / $ABBV, hinting cycle turning. Hated, cash-rich, founder-led setup with M&A/sentiment re-rate optionality. 1% position — asymmetric story risk/reward. Curious about the full approach?👉 Check the @MeanReverter_
1 · Reply
TCork
TCork May. 6 at 8:50 PM
$ABBV is a great name for those looking for defense in this market. Good dividend, nice growth, not too expensive. ABBV should earn more than 14 dollars per share in EPS this year, and a PE around 20 (which is very fair) gets you a 280 dollar stock that's a 30% return or so. And hey if the price doesn't move they'll pay you to own the stock with that dividend.
0 · Reply
Donib11
Donib11 May. 6 at 7:13 PM
$ABBV 230 by end of June? 🤷‍♂️
0 · Reply
Iceman467
Iceman467 May. 6 at 5:19 PM
$ABBV added
0 · Reply
Latest News on ABBV
AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 1 day ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 2 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 2 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 3 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 6 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 6 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 7 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 7 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 7 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 7 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 7 days ago

AbbVie upgraded to Buy at BofA on durable growth

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 7 days ago

AbbVie upgraded to Buy from Neutral at BofA

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:41:09.000Z - 8 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 8 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T16:39:07.000Z - 8 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie says ‘especially pleased’ with immunology and neuroscience results

2026-04-29T13:25:07.000Z - 8 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 8 days ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 8 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

2026-04-29T12:15:43.000Z - 8 days ago

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

2026-04-29T12:13:45.000Z - 8 days ago

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 8 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 8 days ago

AbbVie Reports First-Quarter 2026 Financial Results

Options Volatility and Implied Earnings Moves Today, April 29, 2026

2026-04-29T11:05:22.000Z - 8 days ago

Options Volatility and Implied Earnings Moves Today, April 29, 2026

AMZN F GOOG GOOGL META MSFT QCOM

Notable companies reporting before tomorrow’s open

2026-04-28T18:25:46.000Z - 9 days ago

Notable companies reporting before tomorrow’s open

BIIB CAR EAT ETSY GD GEHC GSK

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 9 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 9 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 10 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 14 days ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 14 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 15 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 15 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 18 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 23 days ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 25 days ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 25 days ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 4 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 4 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 4 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 4 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 4 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 5 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 5 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 5 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 5 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 5 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 5 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 6 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 7 weeks ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 7 weeks ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 7 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 7 weeks ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 7 weeks ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 2 months ago

AbbVie Declares Quarterly Dividend

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 10:00 AM EST - 2 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

BeefSchnitzerlin
BeefSchnitzerlin May. 8 at 2:25 AM
$ABBV Added this to my divi port today. Been watching a long time waiting for the drop below 200 to buy but missed it. Looks like a potential higher low here today. Solid long term divi compounder, beat and raised and still dropped? Glad it didn't run away without me.
0 · Reply
Garibs
Garibs May. 7 at 7:51 PM
$ABBV why is this getting smoked?
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 7 at 4:36 PM
$SLS Keep in Mind - while we Continue to See extended - Near Miraculous ALL POOLED Survival in the REGAL Phase 3 Trial AZA + VEN is the Best Available Treatment (BAT) for Control Arm Patients From the AZA+VEN VIALE-A Phase 3 Trial https://www.venclextahcp.com/aml/side-effects/ven-aza-safety-profile.html - Serious adverse events occurred in 86% of patients with VEN+AZA vs 77% of patients with PBO+AZA - Fatal adverse events occurred in 25% of patients with VEN+AZA vs 22% of patients with PBO+AZA 23% FATALITY RATE for Taking BAT Aza+VEN Subsequently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV including VIALE-M and VIALE-T Trials for AML Remission Maintenance.
0 · Reply
RobinCollins1
RobinCollins1 May. 7 at 4:34 PM
$INMD starting to look like the $ZIM of med-tech. 🧬 Market Cap: $870M / Cash: $530M. Basically no debt, strong FCF, and $82M revenue last quarter. The business is finally stabilizing, but the governance is a wild ride. Moshe Mizrahy's "strategic review" vanished once higher outside bids surfaced. Now, expenses are mounting and operating leverage is suppressed. Is management intentionally keeping the price down while Mizrahy and the company aggressively buy back shares? 🤨 Despite the drama, the aesthetics sector is recovering ($EOLS $ABBV). Even InMode’s growth is returning. With the CFO and Chairman out, the setup is bizarre: A hated, founder-controlled company with half its value in cash, massive buybacks, and a business turnaround that everyone is ignoring. Curious about the full approach? 👉Check the @RobinCollins1
1 · Reply
scottybebs
scottybebs May. 7 at 3:35 PM
$ABBV if your not Ai in this market your nothing this is insane why is it down everyday
0 · Reply
Options_Destroyer
Options_Destroyer May. 7 at 3:23 PM
$ABBV $AMGN $TPR added
0 · Reply
MeanReverter_
MeanReverter_ May. 7 at 3:21 PM
$INMD feels like the $ZIM of med-tech. $870M mkt cap vs ~$530M cash, near zero debt. Still generating ~$82M quarterly revenue with strong margins + FCF — not broken, just mispriced. Story driven by founder control + perception: Mizrahy historical selling, strategic review + rumored bids (incl. foreign interest), then process goes quiet. Buybacks + insider accumulation + exec turnover keep governance discount in play. Aesthetics recovery showing up across $EOLS / $ABBV, hinting cycle turning. Hated, cash-rich, founder-led setup with M&A/sentiment re-rate optionality. 1% position — asymmetric story risk/reward. Curious about the full approach?👉 Check the @MeanReverter_
1 · Reply
TCork
TCork May. 6 at 8:50 PM
$ABBV is a great name for those looking for defense in this market. Good dividend, nice growth, not too expensive. ABBV should earn more than 14 dollars per share in EPS this year, and a PE around 20 (which is very fair) gets you a 280 dollar stock that's a 30% return or so. And hey if the price doesn't move they'll pay you to own the stock with that dividend.
0 · Reply
Donib11
Donib11 May. 6 at 7:13 PM
$ABBV 230 by end of June? 🤷‍♂️
0 · Reply
Iceman467
Iceman467 May. 6 at 5:19 PM
$ABBV added
0 · Reply
Garibs
Garibs May. 6 at 5:16 PM
$ABBV no love for this stock??
0 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 3:38 PM
$ABBV Current Stock Price: $204.59 Contracts to trade: $205.0 ABBV May 08 2026 Call Entry: $1.81 Exit: $3.43 ROI: 89% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Game_Day
Game_Day May. 6 at 1:37 PM
PASS 🏆 $ABBV $BDRX $CABA $PAAS
0 · Reply
Quantumup
Quantumup May. 6 at 11:12 AM
Stifel y'day⬆️ $SYRE's PT to $107 (was $92), reit'd at Buy/said: Following best-in-class UC PoC data for SPY001 (α4β7), SYRE is well-positioned heading into additional PoC cohorts for SPY002 (TL1A) and SPY003 (IL-23p19) in mid-year/3Q26. $JNJ TAK APGE ABVX $ABBV Here's what else Stifel had to say: https://x.com/Quantumup1/status/2051982840607215753?s=20
0 · Reply
Game_Day
Game_Day May. 6 at 3:08 AM
MAY 6 watchlist 📊 Potential reach $ABBV 208.96+ $PAAS 53.78+ (earnings) $CABA 4.48+ (EV+) $BDRX Follow for great stocks watch ideas
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 7:10 PM
$SLS While we Continue to See Near Miraculous survival in all pooled patients, BAT for control Arm Patients Recently Failed, 3 large Phase 3 Trials conducted by $ABBV - Miraculous Survival in this Phase 3 REGAL Trial for Second Remission Maintenance CR2 - VIALE-M Aza+VEN Phase 3 Trial FAILURE for First Remission Maintenance CR1 3 P3 Fails for BAT --- it is not complicated.
0 · Reply
SellasgpsCurativeBAT9
SellasgpsCurativeBAT9 May. 5 at 6:18 PM
$SLS 125 Million+ Cash on hand per last 10K filing. Gps will be CURATIVE in over 20+ WT1 cancer Types. GPS Ad Infinitum Dosing will generate over $50 Billion+ annually for Big Pharmaceutical Suitors. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $ABBV for $10.1B - this is just 1 comp worth $10B. SLS009 has already shown 4 times better response in phase 2b than current SOC. Bidding war is coming $280 Per share. Don’t step over hundred dollar 💵 Bills to pick up Pennie’s. Hold with Conviction. ✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 5 at 5:00 PM
$ABVX $SLS From $5 and change to a High of $148 - from $270M to $14B in Market Value - all based on the Value of a Phase 3 Registrational Catalyst. - GPS Phase 3 Results Are Coming and we ARE IN THE 80th Event WINDOW - While we continue to see Miraculous all pooled survival in the REGAL Phase 3 Trial, among Control Patients on BAT and GPs Combined ... BAT / Aza+VEN Recently FAILED 3 Large Phase 3 Trials, conducted by $ABBV including Failing 2 AML Remission Maintenance Trials ... Aza+Ven is Effective at Getting Front Line patients into Remission, but its not Durable - as Dr. Yair Levy Dir. of Heme Research at Baylor Med Stated. It is not complicated - Gps is the only reason we are seeing the Extended Survival in the Regal P3. 25 Months Since the Last Patient Enrolled, we are likely to see the Final Analysis Top Line Results ANY DAY NOW. And Gps is worth every bit of $40B to Big Pharma the INSTANT we see the PR.
1 · Reply
Th3M4skedSt0nker
Th3M4skedSt0nker May. 5 at 1:23 PM
$KYTX our new CCO Mrs. Nadia Dac made her marks throughout the industry working at $LLY $JNJ $PFE $ABBV & Novartis Network is everything for scaling this baby with a proper GTM 💲💲💲
1 · Reply
FuegoFiesta
FuegoFiesta May. 4 at 10:10 PM
$HAL $ABBV $EME $KMI mie
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 8:01 PM
$SLS $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 4 at 7:53 PM
$SLS Look at the share price when the 72nd event was announced - what do you think will happen when we see the 80th? SLS Market Cap is now up over 1,000% Since the IDMC Unblinded Actual Phase 3 MOS and IR data from the INTERIM ANALYSIS at 60 Events DEC 2024. +1,000% For a Reason --- The unblinded data - Gave most HEME Industry Players $ABBV $PFE the sign Gps is Golden, now 6 months since the 72nd Event, and this far along - 25 months since enrollment completed, and median follow-up of 31 months (25-63) ALL Smart Investors must reconcile the fact the 80th event and instant share price launch could occur at any time. Now 31 months Follow-Up in a setting of "High Leukemic Risk" Dr. Kantarian Chair of MD Anderson's Leukemia Dept., REGAL Phase 3 Global Lead and Steering Committee Chair.
0 · Reply